参考文献/References:
[1]晏俊芳,于浪,孙玉亮,等.以CT图像为基础的宫颈癌三维腔内放疗[J].中华放射肿瘤学杂志,2014,23(5):377-381.[2]张宁,赵志鹏,程光惠,等.局部晚期宫颈癌腔内联合组织间插植3D-IGBT的剂量学研究[J].中华放射肿瘤学杂志,2015,24(3):267-270.[3]陈静,丁乾,罗鸣,等.宫颈癌调强放射治疗的临床研究[J].华中科技大学学报(医学版),2015,41(3):353-357.[4]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.[5]贾彦召,余杰,饶石磊.宫颈癌三维适形放疗与二维放疗计划的比较分析[J].中国实用医药,2015,10（5）:61-62.[6]Patankar SS,Tergas AI,Deutsch I,et al.High versus low-dose rate brachytherapy for cervical cancer[J].Gynecol Oncol,2015,136(3):534-541.[7]刘培培,曹永珍.容积旋转调强与固定野调强在宫颈癌根治性放疗中的剂量学比较[J].中国辐射卫生,2015,24(2):109-112.[8]王承伟,冯志俊,徐惠,等.宫颈癌ＶＭＲＴ与常规４野放疗中的剂量学比较及近期疗效观察[J].江苏大学学报,2015,25(4):322-325.[9]张基永,林珠,吴丽丽,等.图像引导的自适应放疗在宫颈癌治疗中的应用[J].山东医药,2015,55(27):38-39.[10]毛世华,张涛,谈宗国,等.178例宫颈癌放疗疗效及预后相关因素分析[J].实用癌症杂志,2014,29(7):829-831.[11]Mazeron R,Castelnau-Marchand P,Escande A,et al.Tumor dose-volume response in imageguided adaptive brachytherapy for cervical cancer:A meta-regression analysis[J].Brachytherapy,2016,15(5):537-542.[12]陈艳,廖妮红,黄雪芳,等.顺铂联合多西他赛同步放化疗治疗中晚期宫颈癌的临床观察[J].实用癌症杂志,2014,29(6):699-701.[13]齐曼,宋冀,郑艳杰.调强放疗与三维适形放疗治疗局部晚期宫颈癌的临床疗效及毒副作用观察[J].实用癌症杂志,2015,30(5):698-700.[14]阴骏,李鹏程,范子煊,等.局部晚期宫颈癌自适应放疗剂量学及生存分析与毒性反应评价[J].肿瘤预防与治疗,2017,44(4):236-238.[15]金红艳,刘倩,葛四平,等.尼妥珠单抗联合调强放疗及周期化疗治疗局部晚期宫颈癌的临床观察[J].实用癌症杂志,2017,32(3):461-463.[16]Ghorbani M,Hashempour M,Azizi M,et al.Evaluating the effect of various intracavitary applicators on dosimetric parameters of (192)Ir, (137)Cs, and (60)Co sources[J].Australas Phys Eng Sci Med,2016,39(2):477-491. [17]梁克,何少琴,冯炎. 快中子及X射线诱导人食管癌细胞凋亡的研究[J]. 中华放射肿瘤学杂志,2000,9(1):38. [18]孙小梅,丁丽娟,董丽华,等.容积旋转调强与固定野调强在晚期宫颈癌放疗的剂量学比较及疗效观察[J].中华放射医学与防护杂志,2016,36(7):509-512.[19]Tuntipumiamorn L,Lohasammakul S,Dankulchai P,et al.Comparison of impact of target delineation of computed tomography-and magnetic resonance imaging-guided brachytherapy on dose distribution in cervical cancer[J].J Contemp Brachytherapy,2018,10(5):418-424.[20]王嘉琪,李静,宋海涛.调强放疗与三维适形放疗联合腔内后装放疗治疗中晚期宫颈癌的对比研究[J].实用临床医药杂志,2015,19(17):67-70.[21]刘艳,张洁,佐合拉古丽·木塔力甫,等.宫颈癌常规放疗与图像引导的调强放疗近期并发症及疗效的对比[J].实用医学杂志,2016,32(2):211-214.[22]薛涛,刘光波,袁香坤,等. 宫颈癌近距离腔内放射治疗中膀胱和直肠ICRU参考点剂量和体积剂量受量比较[J]. 中国医学物理学杂志,2017,34(9):897-901. [23]栾朝辉,宋梅,于娟,等.调强放疗与三维适形放疗治疗老年中晚期宫颈癌的疗效观察[J].中华老年医学杂志,2016,35(10):1103-1106.[24]余进进,商文庆,董春林.调强放疗联合腔内后装治疗中晚期宫颈癌的临床疗效[J].江苏医药,2016,42(16):1814-1816.[25]高汝斌,仇红,辛红梅.手足软组织良性肿瘤MRI分析[J]. 实用放射学杂志,2016,32(6):982-984. [26]邓小丽.DCe-MRI定量分析在软组织肿瘤的应用价值初步研究[D].大连医科大学,2016.
相似文献/References:
[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Medical Information,2018,31(10):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]袁东方,张刚刚.恶性肿瘤病历主要诊断选择思路分析[J].医学信息,2018,31(07):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
YUAN Dong-fang,ZHANG Gang-gang.Analysis of Main Diagnostic Options for Malignant Tumor Records[J].Medical Information,2018,31(10):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
[3]徐 洁.宫颈癌筛查及预防的研究进展[J].医学信息,2018,31(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Medical Information,2018,31(10):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[4]黄 花,徐冬冬,章丽霞.TGF-β1在宫颈癌中的研究进展[J].医学信息,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Medical Information,2018,31(10):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[5]夏易曼娜,李虎成.腹腔镜下宫颈癌根治术与传统开腹手术的对比研究[J].医学信息,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Medical Information,2018,31(10):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[6]杨 军,王翠平,李 龙,等.义安区体检HPV-DNA筛查结果分析[J].医学信息,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Medical Information,2018,31(10):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[7]王双英,张 娜,刘 芳.具有高危复发因素的早期宫颈癌术后辅助治疗进展[J].医学信息,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Medical Information,2018,31(10):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
[8]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者
分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Medical Information,2018,31(10):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[9]吴晓玲,周桂华.miR-187在宫颈癌中的表达与临床病理关系的研究[J].医学信息,2018,31(16):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
WU Xiao-ling,ZHOU Gui-hua.Expression of miR-187 in Cervical Cancer and Its Relationship with Clinicopathological Features[J].Medical Information,2018,31(10):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
[10]夏为书,彭莉贞,钟清玲.我国宫颈癌患者配偶生活质量评价的研究现状[J].医学信息,2018,31(23):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
XIA Wei-shu,PENG Li-zhen,ZHONG Qing-ling.Research Status of Spouse Quality of Life Evaluation of Cervical Cancer Patients in China[J].Medical Information,2018,31(10):41.[doi:10.3969/j.issn.1006-1959.2018.23.012]
[11]张 慧.宫颈癌放化疗的选择[J].医学信息,2021,34(11):66.[doi:10.3969/j.issn.1006-1959.2021.11.020]
ZHANG Hui.Choice of Radiotherapy and Chemotherapy for Cervical Cancer[J].Medical Information,2021,34(10):66.[doi:10.3969/j.issn.1006-1959.2021.11.020]